Human colon carcinomas (CCs) represent a growing worldwide problem. One of the pathways that has been negatively implicated in the genesis of CCs is triggered by bone morphogenetic protein (BMP) ligands, which activate BMP receptors leading to the function of SMAD proteins in the nucleus. BMP signaling is altered in familial human polyposis, and mice with compromised BMP signaling in the intestine develop tumors. Here, we have re-evaluated the presence and roles of BMP signaling in advanced sporadic human CCs, using both primary tumors and established cell lines, and directly modulating BMP pathway activity in a cell-autonomous manner using constitutively active and dominant-negative BMP receptor Ib forms. We find evidence for active endogenous BMP signaling in all primary CC samples and for its role in promoting primary CC tumor growth and CC cell survival and proliferation in vivo in xenografts. In vitro, we also document autonomous and non-autonomous effects of enhanced BMP receptor activity on gap closure in culture, suggesting possible roles in invasion. Caution should thus be exerted in trying to augment or restore its activity for therapeutic purposes. In contrast, we raise the possibility that blockade of BMP signaling might have beneficial effects against at least a subset of advanced colon cancers.
Introduction
Colon cancer incidence is growing around the globe (American Cancer Society, Cancer Research UK; Jemal et al., 2009) . Although there is efficient treatment for early and localized disease involving surgery, a significant number of patients presenting advanced localized colon carcinomas (CCs) already have or will develop liver metastases, and metastatic CCs remain largely incurable. There is thus a pressing need to re-evaluate current ideas and to find novel ways to treat CCs and metastatic disease.
Several transcription and secreted factors have been implicated in the genesis of intestinal tumors in humans and mice. For instance, activation of the WNT -TCF signaling pathway is essential for the formation of human and mouse intestinal adenomas and most CCs harbor an activated pathway through loss of APC, which normally acts to promote b-catenin degradation, or through direct constitutive activation of b-catenin (Cho and Vogelstein, 1992; Powell et al., 1992; Morin et al., 1997; Sparks et al., 1998) . Other pathways cooperate or synergize with WNT signaling. For example, the NOTCH pathway is implicated in the formation of adenomas in mice (van Es et al., 2005; Fre et al., 2009) , and HEDGEHOG-GLI signaling is essential in advanced human tumors, including liver metastases (Varnat et al., 2009) , acting in parallel with WNT signaling in mice (Arimura et al., 2009; Varnat et al., 2010a ).
An additional pathway implicated in intestinal tumor formation is that triggered by the secreted bone morphogenetic protein (BMP) ligands. The numerous BMPs are members of the transforming growth factor-beta (TGF-b) superfamily. It is estimated that 80% of human colorectal cancers harbor mutations affecting at least one component of TGF-b superfamily signaling (Grady et al., 1999; Blobe et al., 2000) . Moreover, there is a tight link between loss of BMPR1a or SMAD4 and juvenile polyposis, a syndrome characterized by the early appearance of multiple precancerous masses in the intestine with increased risk to develop colon cancers (Howe et al., 1998; Zhou et al., 2001) .
BMP signaling involves a complex pathway with multiple levels of regulation. In the core pathway, BMP ligands bind BMPRII and BMPRI transmembrane tyrosine kinase receptors promoting their heterodimerization and the phosphorylation of BMPRI by BMPRII. Phosphorylated BMPRI receptors then transduce the BMP signal intracellularly by phosphorylating SMAD1, 5 and 8, and it is the action of such phospho-SMADs, in cooperation with SMAD4, that activates BMP target genes (Lagna et al., 1996; Massague, 1996; Kretzschmar et al., 1997; Ló pez-Rovira et al., 2002) . However, the phenotype of SMAD4 KO mice raises the possibility of SMAD4-independent BMP functions (Sirard et al., 1998; Derynck and Zhang, 2003) , suggesting that the presence or absence of SMAD4 might have functional relevance.
The results summarized above support the widespread and accepted notion that BMP signaling acts as a tumor suppressor for sporadic human CCs (Hardwick et al., 2008) . Indeed, immunochemical analyses of BMP pathway components have suggested the loss of BMP signaling in CCs (Kodach et al., 2008a, b) . BMP3 inactivation is a frequent event in CCs and its addition decreases CC colony formation in vitro (Loh et al., 2008) . Moreover, exogenous BMP signaling is reported to inhibit CC cell line growth in vitro (Lee et al., 2010) . BMP signaling can also have tumor-suppressive effects on other cells (Nishanian et al., 2004; Piccirillo et al., 2006) . To our knowledge, however, in vivo experiments in mice supporting the tumor-suppressive role of BMP signaling in advanced human CCs have not been reported.
Other lines of evidence suggest a more complex scenario for BMP signaling in CCs. For instance, BMP signaling appears to be intact in primary CCs (Beck et al., 2006) ; BMPRI receptors are expressed in all CC cells tested (Kodach et al., 2008b; Lee et al., 2010) ; BMP4 expression is found at higher levels in late CCs than in adenomas or normal colonic mucosa (Deng et al., 2007) ; some CC cell lines are resistant to induced differentiation and growth suppression by BMP4 (Nishanian et al., 2004) ; BMP7 can have pro-invasive activity on CC cells independent of SMAD4 (Grijelmo et al., 2007) ; BMP4 overexpression promotes invasiveness of CC cells with or without SMAD4 (Deng et al., 2007 (Deng et al., , 2009 ; and BMP2 induces the epithelial-mesenchymal transition in CC cells (Kang et al., 2009) . Therefore, the role of BMP signaling in human advanced CCs is far from clear (Thawani et al., 2010) . BMP signaling could have multiple roles in various contexts, for instance acting initially as a tumor suppressor and later as a tumor promoter, as proposed for the TGF-b superfamily in different tumors (Blobe et al., 2000; Xu and Pasche, 2007) .
To investigate the role of BMP signaling specifically in advanced human CCs, we have sought to test the consequences of autonomously altered levels of endogenous P-SMAD1,5,8, the mediators of BMP signaling, adopting a strategy previously used to analyze cartilage development (Zou et al., 1997) and forebrain patterning (Gulacsi and Lillien, 2003) in vivo. Namely, we have used constitutively active and dominant-negative forms of BMP receptor Ib (BMPRIb) (also known as ALK6) to enhance or reduce P-SMAD1,5,8 levels. These forms are encoded in mutant cDNAs expressed from replication-incompetent lentiviral vectors (LV), which insert into the genome upon infection and remain stable, at low copy number given the low multiplicity of infection (MOI of 1-3) used, and act cell-autonomously. With this strategy, we should thus be able to alter P-SMAD1,5,8 levels only in CC cells in vitro and in vivo, not directly affecting the stroma as it would be the case in vivo using BMP ligands or secreted antagonists.
Using these tools, we have studied the effect of the mutant receptors in primary CC cells and in established CC cell lines, both in vitro and in vivo. Here, we present evidence that BMP signaling has tumor-promoting activity in vivo in primary CCs, but not in established cell lines, and that a subset of primary tumors require endogenous BMP signaling for normal growth in vivo. Our data support the notion that BMP signaling has multiple roles in tumorigenesis, including an oncogenic action in advanced CCs, making its blockade a possible therapeutic target for advanced disease.
Results

Human CC cells harbor active BMP signaling
To begin to characterize the status of BMP signaling in human CCs, we tested for the expression of mRNAs encoding key pathway elements in three advanced primary CCs and three CC cell lines ( Figure 1A ; Varnat et al., 2009) : CC14 is a tumor node metastasis (TNM) stage 4 local tumor, CC36 is a TNM3 local tumor and mCC11 is a TNM4 liver metastasis. We have also chosen three CC cell lines that represent various kinds of CCs. Ls174T is a near-diploid cell line with an activation mutation in b-catenin, SW480 is a cell line with a loss of function mutation in APC that also lacks SMAD4 and DLD1 is a microsatellite unstable cell line harboring mutant APC. As control, we used a sample of normal human colon.
RT-PCR analyses of these various samples revealed the ubiquitous presence of BMP2, BMP4, SMAD5 and SMAD1 albeit at different levels. SMAD8 was expressed in at least half of the samples tested, whereas the BMP inhibitors CHORDIN and GREMLIN (Walsh et al., 2010) were only expressed in one sample each ( Figure 1A) . The ubiquitous presence of BMP ligands and of SMAD1,5,8, which mediate BMP signaling, suggested an active pathway. Interestingly, SMAD4 was present at high levels only in the primary tumors ( Figure 1A) . The three primary tumors expressed 110-fold more SMAD4 than the three cell lines tested on average (73-fold not counting SW480, that is known to lack SMAD4; Zhang et al., 1996) . Expression levels in normal colon were low, likely owing to the dilution of the different cell types in the heterogeneous sample.
To test whether BMP ligands were expressed at higher or lower levels in the samples chosen when compared with normal human colon, quantitative RT -PCR was used to measure mRNA levels. These are shown as the ratios of the expression in the given sample over the average expression in two independent samples of normal human colon ( Figure 1B) . Notably, BMP2 was underexpressed and BMP4 overexpressed in all the samples ( Figure 1B , shown as the ratios of normalized expression in CC cells over the normalized expression in normal human colon). This raised the possibility that BMP4 signaling could have a role in CC.
To ascertain that BMP signaling is active in all CC cells analyzed, and since BMPRIa/b expression is ubiquitous in all CC cells analyzed (Deng et al., 2007; Kodach et al., 2008a, b; Lee et al., 2010) , we tested for the presence of phosphorylated (P-) SMAD1,5,8, as these are present only in cells with active BMP receptors, which are normally triggered by the presence of BMP ligands. Western blot analyses using an antibody that recognizes only the P-SMAD1,5,8 isoforms showed that all CC samples tested harbor active P-SMADs, albeit at different levels ( Figure 1C) . Quantification of expression levels revealed a +20-fold range, with CC14 at the low end and Ls174T at the high end.
Thus, data indicate that all primary CC cells and CC cell lines appear to harbor active BMP signaling albeit at different levels.
Modulation of BMPRIb receptor activity alters P-SMAD1,5,8 levels
Since BMP signaling is triggered by ligands activating type II and type I BMP receptors leading to P-SMAD1,5,8 action (Figure 2A) , we have used the previously characterized constitutively active (ca) and dominant-negative (dn) BMPRIb forms (Zou et al., 1997 ) that we have cloned in GFP + (green fluorescent protein) LV ( Figure 2B ). The caBMPRIb mutant harbors a Q203D substitution that enhances kinase activity independent of ligand-BMPRII regulation, and the dnBMPRIb mutant harbors a K231R substitution that diminishes its kinase activity ( Figure 2B and C). In addition, the lentivectors used also express GFP in a ubiquitous manner ( Figure 2B ). These dominant mutant BMPRI forms should alter endogenous P-SMAD1,5,8 levels.
Transduction of CC cells with these GFP + replicationincompetent lentivectors as well as with the GFP + parental lentivector as control, followed by FACS-sorting for GFP fluorescence to insure a homogeneously transduced cell population, showed the expected modulation of P-SMAD1,5,8 levels ( Figure 2D ), confirming that these constructs enhance in the case of the caBMPRIb, or diminish in the case of the dnBMPRIb, BMP signaling. Quantification of the protein levels normalized to HSP90 revealed that, compared with control lentivector transduced cells, those expressing caBMPRIb or dnBMPRIb had 200%-550% more or 50%-75% less P-SMAD1,5,8, respectively ( Figure 2D ).
To further verify that the caBMPRIb and dnBMPRIb constructs had the specific effects expected on the BMP pathway, RTqPCR analyses were performed with transduced, GFP + FACS-purified CC36 cells. Gene-expression values were then normalized by the geometrical mean of the housekeeping genes GAPDH and HMBS. Changes are presented as ratios of normalized gene expression in caBMPRIb or dnBMPRIb over those in control cells ( Figure 2E ). caBMPRIb induced the BMP targets SMAD6 and ID1,2,3 by 200%-300%, whereas their levels were reduced by dnBMPRIb by 40%-60% ( Figure 2E ). These manipulations thus afford a range of modified signaling of +7.5-fold.
Modulation of BMPRIb receptor activity has minor effects on CC cell proliferation and no effects on apoptosis in vitro
To measure cell proliferation, we employed the nucleotide analogue bromodeoxyuridine (BrdU), the incorporation of which directly reports DNA synthesis and thus cells that were in S phase during the pulse. BrdU incorporation was then revealed by immunohistochemistry. Short-term (30 -60 min) BrdU incorporation analyses of transduced cells at +70% confluence showed minor effects, ranging from 10% to 40% changes when compared with controls ( Figure 3A) . CC14, DLD1 and Ls174T were largely unaffected ( Figure 3A and data not shown), whereas CC36 and SW480 showed a small (+12%) but significant increase with caBMPRIb, and cell proliferation in CC36 and mCC11 was also significantly compromised (reduced by +20%) after signaling inhibition by dnBMPRIb ( Figure 3A BMPRIb receptor modulation alters cell behavior in a scratch assay in vitro
The small effects on cell proliferation described above suggested a very minor role of BMP signaling in CC cells in vitro. However, to explore this idea further, we tested for effects of altered BMP receptor signaling using a scratch assay. In this test, cells are grown to near confluency and then empty spaces are created on the Petri dishes by scratching out cells with a blunt spatula, thus making a gap between near-confluent cell populations. Such assay is routinely used to test for altered behavior in the interface of confluent and empty zones, assaying for the closure of the gap left by the scratch. CC14, CC36 and mCC11 primary CC cells were tested in the scratch assay after transduction with control lentivectors or with those expressing caBMPRIb or dnBMPRIb ( Figure 4) . The results after 3 days of culture post-scratch showed that caBMPRIb enhanced gap closure in all three primary CCs tested, whereas dnBMPRIb significantly impeded normal healing in two out of three cases, all when compared with control lentivector transduced cells ( Figure 4A and B). For quantification purposes, the average gap distance observed with control cells was equated to one ( Figure 4B ). The most extreme results were obtained with CC36, in which dnBMPRIb increased the gap width by 40% and caBMPRIb reduced it to ,10% of control width on average ( Figure 3B ), closing it in some cases ( Figure 3A ). These results demonstrate an involvement of endogenous BMP signaling in gap closure. They also suggest that BMP signaling may favor and may be required for enhanced proliferation or migration in zones of asymmetric cell densities.
Increased cell proliferation at the gap edge in cells expressing caBMPRIb
To test if cell proliferation could underlie the abnormal healing of the scratched gap of cells with altered BMPR activity when compared with control cells, we performed BrdU incorporation tests using 15 min pulses before fixation and immunolabeling. These analyses, focusing on the edges of the closing gaps in scratch assays after 2.5 days post-scratch, showed that enhancement of BMPR activity led to a 50% increase in cell proliferation within a 5-cell diameter bilateral zone flanking the gap ( Figure 4C ). In contrast, blockade of BMP activity with dnBMPRIb led to a +20% reduction in cell proliferation in a similar area ( Figure 4C ). BMP activity could thus play a role in positively modulating CC cell proliferation in cases of asymmetric cell densities, such as it occurs in the tumor edges.
Autonomous and non-autonomous effects of BMPRIb activity on cell recruitment to heal a scratch gap
The enhanced gap-healing behavior of cells with increased BMPR activity suggested a method to test if this effect was cell-autonomous. Indeed, this is the expectation, as the action of modified receptors is restricted to the expressing cells and the lentivectors used are replication-incompetent. To verify this idea, we adapted a competition assay we recently developed named the Red/Green assay (Varnat et al., 2009; Zbinden et al., 2010) . Here, cells transduced with a red fluorescent protein (RFP)-expressing lentivector are mixed at a given ratio with GFP-expressing cells that carry lentivectors also expressing a given construct, in this case caBMPRIb or dnBMPRIb. RFP + and GFP + cells are then mixed and allowed to reach +80% confluence. At this time, a scratch is made and the color of cells healing the gap is determined under fluorescent light. The closing gaps of Red/Green scratch assays were then monitored and photographed live, and the color of cells within a +25-cell diameter gap as well as those within the flanking +5-cell diameter border zones quantified ( Figure 4D and E).
For the experimental samples, we used the same 25-cell diameter gap and 5-cell diameter borders as in controls described above, centered on the closing gap ( Figure 4D ). As expected from the proliferation assays ( Figure 4C ), the number of GFP + cells within the bilateral flanking borders increased by 50% upon expression of caBMPRIb ( Figure 4E right) , whereas the number of control RFP + cells within this area did not, whether the sibling GFP + cells mixed in expressed caBMPRIb or not ( Figure 4E right) . This result suggests the cell-autonomy of BMPRIb effects. However, within the 25-cell diameter gap being healed, the number of both GFP + and RFP + populations increased 3-fold and 2.5-fold, respectively, when green cells also expressed caBMPRIb when compared with those in which the green cells expressed only GFP ( Figure 4E left) . This non-cell-autonomous effect when green cells expressing caBMPRIb on red control cells suggests a non-cell autonomous recruitment effect to heal the gap independent of cell proliferation. Cells with an active BMP pathway might thus signal adjacent cells to change behavior.
Modulation of BMPRIb activity in CC cells modifies the growth of primary but not established cell line tumors in mouse xenografts
The results with the scratch assays raised the possibility that the asymmetric tumor cell densities may trigger a participation of BMP signaling in tumor growth and possibly invasion. Indeed, the edges of growing tumors are sites of enhanced proliferation and invasion into surrounding tissues. Thus, to test the idea that BMP signaling may enhance tumor growth in vivo, we have modulated BMP signaling with the BMPRIb constructs described above in cells engrafted into immunocompromised mice. Injection of 5 × 10 5 cells transduced with GFP + control, caBMPRIb or dnBMPRIb lentivectors was performed subcutaneously in the flank of immunocompromised mice as previously described (Varnat et al., 2009) . To insure homogeneous cell populations, injected cells were previously FACS-sorted for GFP fluorescence. Tumor measurement was performed daily after it was palpable, which occurred about 7-10 days after injection. Strikingly, all three primary CCs (CC14, CC36 and mCC11) with caBMPRIb, and thus with boosted BMP signaling, showed much enhanced growth when compared with controls, reaching 3-7-fold higher volumes ( Figure 5A and B), and CC36 and CC14 responded to diminished endogenous signaling ( Figure 5A and B). Unlike the clear results obtained with primary CCs, tumors from all three established CC cell lines failed to show any response to either caBMPRIb or dnBMPRIb: the growth curves of control and experimental tumors overlapped ( Figure 5C ).
Overall tumor CC xenograft histology remained unchanged ( Figure 6A ; Varnat et al., 2009) , and BrdU-incorporation analyses in vivo showed an enhancement in tumors expressing caBMPRIb when compared with control tumors at the tumor edges, where proliferating cells are found ( Figure 6B ). These changes were correlated with the decreased or enhanced detection of P-SMAD1,5,8 in large human tumor cells of xenografts expressing dnBMPRIb or caBMPRIb, respectively, when compared with controls and not in small mouse stromal cells ( Figure 6A ). dnBMPRIb did not affect BrdU incorporation in CC14 or mCC11 tumors, and CC36 tumors were not available for testing as these did not grow ( Figure 6B) . No overt changes in the stroma were detected.
BMPRIb activity has a cell survival function in vivo
Analyses of apoptotic cell death with activated Caspase 3 immunolabeling revealed a significant increase in CC14 and mCC11 tumors harboring dnBMPRIb when compared with control tumors ( Figure 6C ). CC36 tumors with dnBMPRIb could not be tested as these did not develop (see above; Figure 6C ). Enhanced activation of BMP signaling with caBMPRIb did not significantly decrease the number of apoptotic cells less than the control number ( Figure 6C) . Thus, BMP signaling may also have an endogenous pro-survival role in vivo.
Modulation of BMPRIb receptor signaling controls tumor expansion in an autonomous manner
The results presented above strongly suggest that a subset of primary CCs, including CC36 cells, require BMP signaling for tumor growth and that the endogenous levels of pathway activity, To test this idea in a different context, we have employed the Red/Green competition assay in subcutaneous xenografts (Varnat et al., 2009; Zbinden et al., 2010) . Here RFP + controltransduced cells are mixed with challenger GFP + cells.
Expression of GFP or RFP fluorescent markers does not alter tumor kinetics and the resulting tumor in vivo is red and green upon fluorescent illumination ( Figure 7A) , largely preserving the initial red/green ratio (Varnat et al., 2009; Zbinden et al., 2010) . Upon tumor growth, which is always driven by the red population, FACS analyses of the dissociated tumor cells ( Figure 7B) report the relative or competitive growth of one population in comparison with the other. In the present case, in addition to GFP, the same cells also expressed caBMPRIb or dnBMPRIb. Expression of dnBMPRIb or caBMPRIb in the GFP + cells resulted in the reduction or expansion of this population, respectively ( Figure 7C ), shown as the ratio of GFP/RFP cell numbers. We conclude that BMP signaling in tumor epithelial cells regulates CC tumor growth in an autonomous manner.
GLI1 induces BMP4 in primary CC cells
Previous work has demonstrated an essential role of HH -GLI1 signaling in CC stemness, tumor growth and metastases (Varnat et al., 2009) , and has provided evidence for a key role of GLI1 as integrators of oncogenic and loss of tumor-suppressive inputs (Stecca et al., 2007; Varnat et al., 2009; Stecca and Ruiz i Altaba, 2010) . Given this background, we asked if the BMP and HH-GLI pathways might interact as both drive CC growth in vivo ( Figure 5 ; Varnat et al., 2009) . We note that previous work has reported evidence for the direct regulation of BMP4 by GLI1 in COS-7 cells (Kawai and Sugiura, 2001) , and we ( Figure 1 ) and others (Deng et al., 2007) have found high levels of BMP4 in advanced CCs. To test if BMP4 may be regulated by GLI1 in primary CC cells, we transduced CC36 cells with lentivectors expressing GLI1 (Stecca et al., 2007; Varnat et al., 2009; Zbinden et al., 2010) to enhance its activity, mimicking the increase seen at the metastatic transition (Varnat et al., 2009) . Analyses 4 days after transduction revealed that enhanced GLI1 function resulted in 2.3-fold increase in the levels of BMP4 mRNA when compared with parental lentivector-transduced sibling cells, all after normalization with GAPDH and HMBS and as determined by qRT-PCR. Consistent with increased BMP signaling, ID2 was similarly induced 1.6-fold when compared with control cells. These changes mimicked those obtained with caBMPRIb, which lead to 3.9-fold and 5-fold enhancement of the expression of BMP4 and ID2, respectively, as expected. caBMPRIb only lead to a 1.5-fold increase in GLI1 mRNA levels suggesting that there may be a degree of feedback regulation by which enhanced BMP signaling might enhance GLI1 activity, possibly paralleling the boosting of GLI function by TGF-b signaling (Dennler et al., 2007 (Dennler et al., , 2009 ).
Discussion
The BMP pathway is one of the key morphogenetic signaling pathways involved in the patterning of developing animal embryos. BMP signaling is also involved in human cancers. For example, it has been proposed to act as a tumor suppressor for human CCs. This idea largely derives from the finding that BMPRIa or SMAD4 are lacking in juvenile polyposis through germline mutations (Howe et al., 1998; Zhou et al., 2001) , and that their straight loss in mice causes the formation of intestinal masses (Haramis et al., 2004; Hardwick et al., 2008) . These data and the reported loss of P-SMAD1,5,8 in CCs have generally supported the therapeutic enhancement of the BMP pathway as a goal to inhibit sporadic CC growth (Kodach et al., 2007 (Kodach et al., , 2008a Hardwick et al., 2008) .
Contrary to the idea that BMP signaling is lost in sporadic CCs, its presence is supported by the detection of P-SMAD1,5,8, BMP4 and BMP pathway targets such as ID1,2,3 and SMAD6 in CC cell lines and primary cultures (Figures 1 and 2) . Indeed, our expression data are consistent with and extend previous findings (Beck et al., 2006; Deng et al., 2007; Lee et al., 2010) . Therefore, sporadic CCs do appear to harbor BMP signaling activity although the meaning of varying levels between tumors or between CCs and the normal colonic mucosa remains to be addressed, as this pathway is known to act in a dose-dependent manner during development.
Here, we have tested the endogenous role of BMP signaling in CC cells through the modulation of endogenous P-SMAD1,5,8 levels using cell-autonomous tools. Replication-incompetent LV are used to infect tumor cells, which are then FACS-purified and tested in vitro or grafted into mice in vivo. In this way, the only cells having directly altered pathway activity are the human epithelial tumor cells and this population is fully transduced. Indeed, the mouse stroma is not directly affected in the system we have employed, unlike in the case of global treatments with BMP ligands or antagonists (e.g. BMP4 or GREMLIN). Using such lentivector-based cell-autonomous approach, we have recently demonstrated the cell-autonomous requirement of HH-GLI signaling in CCs (Varnat et al., 2009) .
Using the previously characterized BMPRIb mutants (Zou et al., 1997) shown to alter P-SMAD1,5,8 levels in CC cells in vitro (Figure 2 ) and in vivo (Figure 6 ), we show here that primary CC cells respond to elevated BMPR activity by enhanced proliferation and tumor growth in vivo, whereas blockade of BMPR activity leads to impaired growth in two tumor proliferation in all cases. Asterisks denote significant changes (P , 0.05). ns: not significant. Apoptosis was enhanced in xenografts with compromised BMPR activity. Asterisks denote significant changes (P , 0.05). ns: not significant. Scale bar ¼ 30 mm for (A upper panels), 60 mm for (A lower panels, B, C).
of three primary tumors. These are very striking results that call into question the prevalent notion that BMP signaling is a CC tumor-suppressive pathway. Notably, two localized CCs (CC14 and CC36) show an endogenous requirement for BMP signaling, whereas the one liver metastasis tested does not, although the growth of all three is enhanced by increased signaling. Future studies shall clarify if sporadic tumors that require BMP signaling for growth form a particular subset that can be defined molecularly or by its behavior in patients.
The present data also suggest that results in vitro may not predict in vivo function. We find that BMPR-P-SMAD modulation has limited positive effects on cell proliferation and survival in vitro, although other works suggest that BMP inhibitors can promote cell line expansion in vitro (Sneddon et al., 2006) . In contrast, we find that enhanced BMP signaling through caBMPRIb consistently enhances tumor growth of primary CC cells, but not that of cell lines, in vivo. We suggest that the wealth of data on human cancer cell lines in vitro needs to be confirmed in human xenografts before possible extensions are made to patient tumors. Indeed, we have recently shown that the microenvironment alters WNT -TCF and HH -GLI pathway levels and WNT-TCF requirement (Varnat et al., 2010b) , and preliminary data suggest also an enhancement of the BMP target ID1 and ID2 in vitro versus in vivo in xenografts (not shown, see Varnat et al., 2010b) .
In this sense, our data also suggest an invasive function for BMP signaling in CC cells, as seen in the autonomous and nonautonomous effects of gap closure in the scratch assay. Although these results are consistent with the recent data derived from different invasion assays (Grijelmo et al., 2007; Deng et al., 2009; Kang et al., 2009) , they disagree with the reported inability of NOGGIN or BMP7 to affect gap closure in SW480 cultures, while BMP2 had a mild inhibitory effect (Beck et al., 2006) . Future analyses should test for an invasive function of BMP signaling in patient-derived primary CCs in vivo.
Why primary CCs increase their proliferation rates and tumor growth in response to enhanced BMPR activity, whereas established cell lines do not, is unclear. We show that caBMPRIb and dnBMPRIb modulate the endogenous levels of P-SMAD1,5,8 in opposite ways in all cases tested, suggesting that it is not likely an issue with signal transduction. Levels of BMPRIb are also unlikely to account for this difference as CC14 and DLD1 express higher levels than CC36, Ls174T or mCC11, whereas all express BMPRIa (not shown), consistent with the generalized expression of BMPRIa and BMPRIb in CC cells (Deng et al., 2007; Kodach et al., 2008a, b; Lee et al., 2010) . We note that one striking difference between primary tumors and cell lines is the level of expression of SMAD4 (Figure 1) . Therefore, one possibility is that the early loss of BMP signaling (e.g. by loss of SMAD4) promotes polyposis and tumor formation, although if it is not lost or through an alternative route, it can later enhance tumor growth.
Importantly, the data indicate that endogenous BMP signaling is essential for tumor growth in at least a subgroup of CCs, with CC36 showing an absolute requirement. The molecular basis for this behavior is unclear. Further analyses should also address the specificity of BMP pathway activation by various ligands and receptors (Zou et al., 1997; Sahni et al., 2010) ; caBMPRIa and caBMPRIb are reported to act similarly (Ashique et al., 2002) but there is BMPRI isoform specificity in various contexts (Zou et al., 1997; Ashique et al., 2002; Sahni et al., 2010) , raising the possibility that dnBMPRIa might block tumor formation in CCs, which do not respond to dnBMPRIb.
How BMP activity interacts with other CC oncogenic inputs remains unclear. However, the regulation of BMP4 by HH -GLI1 in primary CCs that we report extends previous data on other cells (Kawai and Sugiura, 2001 ) and suggests an integration of oncogenic HH -GLI and BMP pathways in CCs. HH-GLI activity, which increases in metastatic CCs (Varnat et al., 2009) , might therefore drive enhanced expression of BMP4, triggering increased tumor growth and possibly invasion/metastases. GLI1, which integrates oncogenic inputs such as RAS-MEK/AKT and loss of tumor suppressors such as PTEN and p53 (Stecca and Ruiz i Altaba, 2010) , may thus also control cancer growth through the regulation of oncogenic BMP signaling. Interestingly, b-catenin is required for BMP4 expression (Kim et al., 2002) , and BMP signaling suppresses PTEN in CC cells (Beck and Carethers, 2007) . Moreover, WNT-b-catenin/TCF signaling acts in parallel with HH -GLI in mouse intestinal tumors (Arimura et al., 2009; Varnat et al., 2010a) ; PTEN decrease boosts AKT (Beck and Carethers, 2007) , which in turn enhances GLI1 activity levels (Stecca et al., 2007; Varnat et al., 2009) , and, in other cells, GLI2 can be regulated by cooperative SMAD3/b-catenin function (Dennler et al., 2009) . Given these results, we suggest the existence of a cross-functional network in which b-catenin (but not necessarily WNT -TCF (Varnat et al., 2010b) ), HH-GLI and BMP signaling reinforce tumor growth positively and cooperatively.
More generally, we suggest that since BMP signaling can act as a tumor promoter, extreme caution should be exerted in trying to elevate its levels as a therapeutic strategy to eradicate CCs as this may have the exact opposite effect. Instead, the data presented here suggest blockade of BMP signaling as a novel avenue to treat advanced disease.
Materials and methods
Human CC primary cells and cell lines
Primary CC36, CC14 and mCC11 colon cancer cells (Varnat et al., 2009) were derived from fresh human colon cancer samples obtained directly from the University Hospital of Geneva. Tumor dissociation and primary culture were described previously (Varnat et al., 2009) . Ls174T (gift from E. Batlle, Barcelona), DLD1 (ATCC) and SW480 (ATCC) cell lines were cultured in DMEM/F12 supplemented with 10% heat-inactivated FBS.
Lentivectors caBMPRIb and dnBMPRIb containing plasmids were a kind gift of L. Niswander (HHMI, U. Colorado). The fragments were excised from the original pBluescript plasmids and cloned into the GFP-containing pTween lentivector between XbaI and XhoI restriction sites. Lentivirus production was performed transfecting the constructs in 293T cells with calcium chloride and VSV-G envelope plasmid and R8.74 packaging plasmid. Supernatants were harvested 48 and 36 h after transfection, concentrated by ultracentrifugation and titrated by standard techniques as described Stecca et al., 2007; Varnat et al., 2009) . LV-GLI1 was as described in Stecca et al. (2007) and Varnat et al. (2009) . MOI was 1-3.
Immunohistochemistry
Subcutaneous xenografts were dissected from mice and directly frozen in O.C.T. (Tissue-Tek, Sakura). Cryostat sections of 10 mm were fixed in 4% PFA for 15 min. Antigen retrieval was performed by boiling the sections in citrate 0.01 M, pH 6, followed by a 20 min incubation at room temperature (rt) in 3% H 2 O 2 for 20 min and blocked in 10% heat-inactivated goat serum (HINGS) for 1 h. Sections were then incubated with rabbit anti-P-SMAD1,5,8 antibodies (1:200 overnight at 48C; Cell Signaling), biotinylated anti-rabbit secondary antibody (1 h at rt; Vector Laboratories), streptavidin-HRP (30 min, Zymed) and developed with DAB (Sigma). Other immunofluorescent labelings were performed as follows: cryostat sections were fixed in 4% PFA for 15 min, blocked in 10% HINGS and incubated with a rabbit anti-activated Caspase3 (1:100 overnight at rt, Cell Signaling) or rabbit anti-GFP (1:500, overnight at rt, Invitrogen) antibodies. Finally, Cy3-labeled secondary (1 h at rt; Jackson Immuno Research) or FITC-labeled secondary (1:500, 1 h at rt; Invitrogen) antibodies were applied, respectively. Sections were counterstained with DAPI (Sigma) to highlight nuclei. H&E staining was performed following standard procedures.
BrdU incorporation assay
Human primary cells and colon cancer cell lines were infected with LV-caBMPRIb, LV-dnBMPRIb and LV-control. Seventy-two hours after transduction, GFP-expressing cells were FACS-sorted and re-cultured after plating in equal numbers to assess for cell proliferation or apoptosis. After an acute BrdU pulse (30 min), cells were fixed in 4% PFA for 1-2 min, incubated for 15 min in 2N HCl and neutralized in 0.1 M boric acid at pH 8.5 for 10 min. Cells were subsequently blocked in 10% HINGS and labeled with mouse anti-BrdU antibodies (1:5000, 2 h at rt; University of Iowa Hybridoma Bank) and rhodamine-coupled anti-mouse antibodies (1:500, 1 h at rt; Invitrogen) and counterstained with DAPI (Sigma). Ten fields per condition were counted for quantification and expressed as a BrdU/DAPI ratio.
In vivo cell proliferation was assessed by intraperitoneal injection of 100 ml of 20 mg/ml BrdU for 2 h before collection. Cryostat sections of fresh-frozen tumor tissue were fixed and incubated in 2N HCl for 30 min and neutralized in 0.1 M boric acid at pH 8.5 for 15 min. Sections were then blocked in 10% HINGS and labeled overnight with mouse anti-BrdU antibodies (University of Iowa Hybridoma Bank) at 48C. This was followed by incubation with a rhodamine-labeled secondary antibody (Invitrogen) and DAPI (Sigma) as above.
Apoptosis assay
Apoptosis was evaluated by immunofluorescence using a rabbit anti-cleaved Caspase3 antibody. Cells or sections were fixed in 4% PFA for 2 or 10 min, respectively, and blocking was conducted by incubation in 10% HINGS. Rabbit anti-cleaved Caspase3 antibody (1:200, overnight at 48C; Cell Signaling) and Cy3-labeled secondary antibody (1:500, 1 h at rt; Jackson Immuno Research) were used for immunodetection. Cells were counterstained with DAPI (Sigma). Quantification was performed as described above.
Scratch assay
Human primary colon cancer cells infected with LV-caBMPRIb, LV-dnBMPRIb or parental LV-control were plated in 6 cm dishes. When cells reached 80%-90% confluence, several parallel scratches were performed using a blunt spatula 1 mm wide. After 72 h, the result was quantified measuring the gap distance between the edges of the scratch in 10 independent fields per condition. Also, a short BrdU pulse (15 min) was performed and cells were processed by immunofluorescence as described above. To quantify the proliferation in the edge of the gap, BrdU + cells were counted in the specified zones in 10 independent fields per condition and the results were expressed as BrdU/DAPI ratios.
Red/Green scratch assay
The red/green assay (Varnat et al., 2009; Zbinden et al., 2010) was adapted for use in the scratch assay. GFP + CC36 cells infected with BMPR mutant or control lentivectors were mixed at a given ratio with control RFP + sibling cells and plated in 6 cm dishes. When cells reached +80% confluence, several longitudinal and parallel scratches were performed with a blunt spatula. After 2.5 days of further growth, cells were optionally fixed in 4% PFA for 30 sec and the cells (live or fixed) within and near the border were analyzed under fluorescent microscopy with an inverted Zeiss microscope. GFP + and RFP + cells were counted in a 25-cell diameter gap corresponding to the average gap width of control GFP + /RFP + scratched plates. Ten independent fields were counted per condition. In the same fields, GFP + and RFP + cells were also quantified in a 5-cell diameter border area flanking the gap.
RT -PCR and qRT -PCR
RNA extraction was performed with RNeasy Mini Kit (Qiagen) or Trizol reagent (Invitrogen). cDNA synthesis was performed using SuperScript Reverse Transcriptase (Invitrogen) and random hexamers (Roche). Standard RT-PCRs were performed using GoTaq polymerase (Promega) in a PTC-200 thermal cycler (MJ Research), with an of annealing temperature of 608C and 30-35 cycles. Quantitative RT-PCRs were performed at 608C with IQTm SYBR green supermix (Bio-Rad) and an Opticon machine (MJ Research). ImageJ software was used to quantify the intensity of the bands. RT-PCR and qPCR primer sequences are shown in Table 1 .
Western blots
Proteins were extracted using RIPA (1 M Tris, pH 7.4, 10% NP-40, 0.25% NaDoc, 5 M NaCl, 0.5 M EDTA) buffer for 20 min at 48C. The BCA assay (Pierce), based on the ability of proteins to reduce Cu 2+ to Cu + in an alkaline medium, followed by the colorimetric detection of Cu + by bicinchoninic acid, was used to quantify protein lysates. Twenty micrograms of total protein were denatured and separated by SDS-PAGE, transferred onto a nitrocellulose membrane, blocked in 5% skimmed milk and probed with anti-P-SMAD1,5,8 (1:1000, overnight at 48C; Cell Signaling) or anti-HSP90 (1:4000, 1 h at rt; Santa Cruz) primary antibodies, followed by HRP-conjugated secondary antibodies (Promega) and developed with ECL Western Blotting Analysis System (Amersham). ImageJ software was used to quantify the intensity of the bands.
Mouse xenografts of human CC primary cells and cell lines
Human CC primary cells and cell lines were infected with appropriate lentiviral vectors (LV-caBMPRIb, LV-dnBMPRIb and LV-control). Seventy-two hours after transduction, GFPexpressing cells were FACS-sorted and re-plated for overnight culture to allow cells to recover. About 5 × 10 5 sorted cells were re-suspended in HBSS and injected subcutaneously into the flanks of 6-8 weeks old female nude (NMRI) mouse. Tumor volumes were measured daily after their first appearance. Fluorescence of xenografts was monitored in situ in a dark chamber using a green fluorescent excitation laser and a color CCD camera (Lightools, CA, USA). Before tumors reached legal limits, the animals were sacrificed and tumors processed.
In vivo red/green assay
Red/Green assays in vivo (Varnat et al., 2009; Zbinden et al., 2010) were performed infecting primary colon cancer cells either with an RFP-expressing control virus or the GFP-expressing LV-caBMPRIb and LV-dnBMPRIb lentivectors. Each population was FACS-sorted to insure the use of homogeneously transduced cell populations. Red and green populations were then mixed at a given ratio (near 1:1) and injected subcutaneously into the flanks of nude mice as described Stecca et al., 2007; Varnat et al., 2009) . After dissection, tumors were dissociated and cells FACS-analyzed to quantify the RFP + red and GFP + green populations, counting at least 10000 cells.
